Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
merck
6
×
national
national blog main
national top stories
new york blog main
new york top stories
pembrolizumab
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
life sciences
biotech
fda
affordable care act
bristol-myers squibb
cancer
cancer immunotherapy
clinical trials
gene therapy
keytruda
medicare
abbvie
abeona therapeutics
What
bio
roundup
drug
nash
american
based
best
companies
continue
crash
debate
healthcare
industry
kind
new
people
pharmaceutical
policy
politicians
pressure
scalps
trump’s
u.s
acquisitions
albert
approval
approved
arena’s
biggest
biogen’s
biopharmaceutical
bounty
bourla
cancer
ceo
cig
comeback
company
convo
corner
Language
unknown
Current search:
merck
×
pembrolizumab
×
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More